JPRN-jRCT2031220050进行中（未招募）1 期
A CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF NXT007 WITH A NEW PREPARATION METHOD IN HEALTHY JAPANESE MALE ADULTS
Takehiko Sambe0 个研究点目标入组 30 人开始时间: 2022年4月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 44age old（—）
- 性别
- Male
入选标准
- •Able to comply with the study protocol, in the investigators judgment
- •For men who are not surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use condoms, and agreement to refrain from donating sperm, as defined below:
- •- With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 5 half-lives or 12 months after the last dose of NXT007, whichever is longer to avoid exposing the embryo. Men must refrain from donating sperm during this same period.
- •-The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the HV/patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception
- •Japanese race/ethnicity
- •Japanese race/ethnicity
- •Age =>20 and <45 years
- •BMI at screening: (Body weight [kg]/height [m]2) =>18.5 to <25.0
- •Absence of evidence of any active or chronic disease following a detailed medical and surgical history and complete physical examination, vital signs, 12-lead ECG, and laboratory tests
排除标准
- •Previous or current history of drug- or alcohol-dependence
- •Previous or concomitant TE disease such as DVT, or signs of TE disease or TMA
- •Protein C activity (chromogenic assay), protein S free antigen, or antithrombin III activity levels below the lower limit of the reference range at screening
- •History of clinically significant allergy (anaphylactic shock or anaphylactoid symptoms)
- •Previous or concomitant autoimmune or connective tissue disease
- •Previous or concomitant malignancy or leukemia
- •History of hypersensitivity associated with globulin preparations
- •Received or planned to receive a live vaccine within 4 weeks before the start of the study drug administration
- •Planned surgery (including tooth extraction) during the study period
- •Participated in another clinical study within 4 weeks before screening, or within 5 half-lives of the investigational product, whichever is longer
- •Clinically significant ECG abnormalities at screening such as the following:
- •-The average QT interval with Fridericias correction of triplicate-measurements in supine position at 10-minute rest >450 msec.
- •-Bradycardia at rest (average heart rate < 40 bpm)
- •-Tachycardia at rest (average heart rate >100 bpm)
- •-Other clinically significant abnormalities in ECG
- •Any family history of congenital long QT syndrome or known congenital arrhythmiarespiratory, circulatory, endocrine, hematological, gastrointestinal, immune, psychological/nervous system, renal, hepatic, or allergic disorder
- •Family history of TE disorder such as serious DVT
- •Use or planned use of other drugs (i.e., prescription or over-the-counter drugs) within 2 weeks before the start of study drug administration (provided, however, that non-systemic topical antiseptics and ophthalmic solutions not affecting the PK or safety of the study drug will be permitted)
- •Blood draw of 200 mL within 4 weeks or 400 mL within 12 weeks prior to screening (e.g., blood donations), annual total blood draw volume (including blood drawn for this study) exceeding 1200 mL, or blood component donation within 2 weeks prior to screening
- •FVIII activity=>120 IU/dL at screening
- •Positive screening result for HIV antigen/antibodies, HBs antigen, or HCV antibodies. HVs who showed HBs antigen positive due to vaccination against hepatitis B are eligible
- •Evidence of infection at screening
- •Abnormal clinical findings at screening
- •Prior treatment with antibody preparations (commercially available or investigational)
- •Any other reason that, in the judgment of the investigator, would render the subject unsuitable for study participation
研究者
相似试验
招募中
不适用
Clinical pharmacology study to evaluate the pharmacokinetics, safety and efficacy of multi-targetted tyrosine kinase inhibitor regorafenib in Japanese patients with advanced colorectal cancer.Colorectal CancerJPRN-UMIN000013939Showa University School of Medicine100
进行中（未招募）
不适用
CLINICAL AND PHARMACOLOGICAL STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®)PARKINSON'S DISEASEEUCTR2012-001245-40-IT
尚未招募
3 期
Comparative Clinical Study of Kariradi Vaginal Wash and Clotrimazole in ShwetapradarCTRI/2024/07/069717DrApurva Chandrakant Karande
进行中（未招募）
不适用
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disordersEUCTR2012-000792-16-HUOCTAPHARMA AG23
进行中（未招募）
不适用
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disordersEUCTR2012-000792-16-CZOCTAPHARMA AG23